BioSpace News Archive

Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.

Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.

In order to speed up drug development and accelerate target identification, biopharma is increasingly turning to artificial intelligence and machine learning. Most recently, Hong Kong-based Insilico Medicine developed GENTRL, an AI system for drug discovery.

The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”

Pharma stock prices took an across-the-board tumble Tuesday after Speaker of the House Nancy Pelosi unveiled a working plan to lower the prices of 250 of the most expensive drugs covered by Medicare and other government-funded programs.

BioDiscovery, Inc. announced that Children’s Hospital of Los Angeles, an award-winning hospital with comprehensive medical care services and programs for children, has signed on as a BioDiscovery Center of Excellence for Clinical Genomics to serve as a reference site for others seeking information and training on BioDiscovery’s NxClinical software.

It’s been an incredibly busy week so far for San Francisco-based Atomwise, a company focused on using artificial intelligence (AI) for drug discovery. The company has signed three deals this week and it’s only Wednesday.

Some hiring managers will not hire those who don’t thank them; others, given two equal candidates, will choose the one who sent a thank you.

Amphion Innovations plc announces that 1,150,000 shares in Partner Company, Polarean Imaging plc have been sold for partial repayment of the loan facility originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.

At the Combined General Meeting held on September 5, 2019, in Montpellier, shareholders voted to include the MedinCell “Raison d’être” in the company’s articles of association